Skip to content

Isocapnic intermittent hypoxia and endothelial dysfunction

The effects of nitric oxide synthase inhibition on arterial stiffness during short term hypoxic exposure in healthy men

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000280606
Enrollment
10
Registered
2005-09-02
Start date
2003-05-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Subjects will be infused with L-N monomethyl arginine (LNMMA) and saline (placebo) in a single blinded randomized design on two separate days to assess the effect of nitric oxide synthase inhibition on arterial stiffness. Initially there will be a 10 minute baseline period. Then the LNMMA or saline will be infused over 5 minutes, after which there will be another 5 minute baseline period. Following this there will be the 20 minute period of hypoxia and then a 10 minute recovery period. Duri

Subjects will be infused with L-N monomethyl arginine (LNMMA) and saline (placebo) in a single blinded randomized design on two separate days to assess the effect of nitric oxide synthase inhibition on arterial stiffness. Initially there will be a 10 minute baseline period. Then the LNMMA or saline will be infused over 5 minutes, after which there will be another 5 minute baseline period. Following this there will be the 20 minute period of hypoxia and then a 10 minute recovery period. During this the subjects will breathe through a mouthpiece connected to special equipment which delivers different gas mixtures and enables the delivery of the hypoxic exposure. Heart rate blood pressure, arterial stiffness ( via pulse wave analysis), and peripheral vasoconstriction (via peripheral arterial tonometry PAT) will be measured.

Sponsors

NHMRC
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Diagnosis
Masking
Blinded (masking used)

Eligibility

Sex/Gender
Male
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Healthy men

Exclusion criteria

History of obstructive sleep apnoea or cardiovascular or respiratory disease, Smoker, Treatment with cardiovascular or respiratory medication.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026